News

Clinical trials at Huntsman Cancer Institute (HCI) help find better ways to prevent, diagnose, and treat cancer by testing the safety and effectiveness of new drugs and treatments. On average, there are between 150–200 clinical trials open to HCI patients at any given time.

Huntsman Cancer Institute has established The Society of Huntsman Translational Scholars, an initiative that recognizes excellence in the discipline of translational science. Courtney Scaife, MD, was recently honored with a Huntsman Translational Scholar award.

Too many patients with cancers like multiple myeloma relapse after treatment. This grim reality motivated researchers at HCI to try to improve the depth and durability of treatment response in multiple myeloma through a new cancer cell targeting mechanism. In research published in the journal Nature Communications, HCI scientists describe a novel way to treat cancers using chimeric antigen receptor (CAR) T cell therapy.

Huntsman Cancer Institute has established The Society of Huntsman Translational Scholars, an initiative that recognizes excellence in the discipline of translational science. Randy Jensen, MD, PhD, was recently honored with a Huntsman Translational Scholar award.

The International Chronic Myeloid Leukemia Foundation (iCMLf) has awarded the prestigious Rowley Prize to Michael Deininger, MD, PhD. Deininger’s selection as the 2019 awardee was announced in February. Formal presentation of the prize occurred at an international scientific conference in Bordeaux, France, earlier this month.

Researchers at Huntsman Cancer Institute at the University of Utah discovered in laboratory studies that an experimental drug called selinexor may block a crucial survival pathway exploited by myelofibrosis cells.

Pancreatic cancer is relatively rare, but chances are likely you care for several patients with a family member who has been diagnosed with pancreatic cancer. New data insights outline pancreas cancer screening strategies for certain patients with a family history of the disease.

Today the New England Journal of Medicine published the first results of a phase III international clinical study called TITAN, which evaluated the effectiveness and safety of a new drug, apalutamide, to treat advanced prostate cancers.